Valuation: Catalyst Pharmaceuticals, Inc.

Market Cap 385.5Cr 337.35Cr 310.9Cr 288.17Cr 547.04Cr 37TCr 555.85Cr 3.73TCr 1.45TCr 18TCr 1.45TCr 1.42TCr 62TCr P/E 2026 *
16.1x
P/E 2027 * 13.1x
Enterprise Value 385.5Cr 337.35Cr 310.9Cr 288.17Cr 547.04Cr 37TCr 555.85Cr 3.73TCr 1.45TCr 18TCr 1.45TCr 1.42TCr 62TCr EV / Sales 2026 *
6.06x
EV / Sales 2027 * 5.37x
Free-Float
94.43%
Yield 2026 *
-
Yield 2027 * -
1 day-0.11%
1 week+0.11%
Current month+0.11%
1 month+0.59%
3 months+25.91%
6 months+38.49%
Current year+34.81%
1 week 31.43
Extreme 31.43
31.5
1 month 31.28
Extreme 31.28
31.5
Current year 22.13
Extreme 22.13
32.56
1 year 19.05
Extreme 19.05
32.56
3 years 11.55
Extreme 11.55
32.56
5 years 4.81
Extreme 4.81
32.56
10 years 0.68
Extreme 0.68
32.56
Manager TitleAgeSince
Chief Executive Officer 65 01/01/2024
Director of Finance/CFO 55 01/01/2024
Compliance Officer 62 29/02/2016
Director TitleAgeSince
Chairman 78 01/01/2002
Director/Board Member 62 01/10/2002
Director/Board Member 65 19/02/2015
Date Insider Type Main position Quantity % Market Cap.
03/06Fiscal year

Chief Technology Officer

3,795 0.0031%
17/02Fiscal year

Head of Human Resources

1,585 0.0013%
05/01Fiscal year

Chief Executive Officer

94,787 0.0771%
Change 5-day change 1-year change 3-year change Capi.($)
-0.11%+0.11%+50.19%+155.19% 385.5Cr
+4.00%+8.28%+25.47%-2.49% 6.61TCr
-0.24%-3.13%+49.38%+223.97% 5.53TCr
+1.21%+42.20%+42.20%+42.20% 4.24TCr
-0.21%+7.44%-48.93%-54.50% 4.13TCr
-2.44%+13.17%+165.05%-33.33% 3.25TCr
-0.74%-4.17%+59.11%-24.73% 3.08TCr
+1.81%+3.79%+74.91%+89.56% 2.31TCr
-3.65%+8.93%+1.16%+184.50% 2.01TCr
-0.04%+3.85%+67.76%+135.89% 1.72TCr
Average -0.04%+4.81%+48.63%+71.63% 3.33TCr
Weighted average by Cap. +0.48%+4.11%+43.52%+55.99%

Financials

2026 *2027 *
Net sales 64Cr 56Cr 51Cr 48Cr 90Cr 6.04TCr 92Cr 615.24Cr 239.26Cr 2.98TCr 238.85Cr 233.68Cr 10TCr 72Cr 63Cr 58Cr 54Cr 101.87Cr 6.81TCr 103.51Cr 694.24Cr 269.98Cr 3.36TCr 269.52Cr 263.68Cr 12TCr
Net income 23Cr 20Cr 19Cr 17Cr 33Cr 2.19TCr 33Cr 223.52Cr 87Cr 1.08TCr 87Cr 85Cr 3.74TCr 32Cr 28Cr 26Cr 24Cr 45Cr 3TCr 46Cr 305.81Cr 118.92Cr 1.48TCr 118.72Cr 116.15Cr 5.12TCr
Net Debt - -
Logo Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
Employees
182
Date Price Change Volume
08/26/08 $31.46 -0.13% 4,81,798
06/26/06 $31.50 +0.16% 9,23,751
02/26/02 $31.45 +0.03% 16,16,291
01/26/01 $31.44 +0.03% 8,16,919
30/26/30 $31.43 -0.10% 47,66,667
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
31.50USD
Average target price
31.67USD
Spread / Average Target
+0.53%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CPRX Stock